Medical World News

[Preciouslife1]

With respect to exosome testing, PPHM has published "Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine."

Images of tumor location show clearly in a PET scan. Any metastases should also be evident in a scan.

http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0084864&type=printable

Exosome test tells doctors/patients that there is a significant quantum of PS-positive exosomes in the patient's system. The next step would be a conformational and locational scan.

Peregrine ran a human trial at Washington University School of Medicine, started June 2012, and closed out on schedule, March 2016. Peregrine has that data.

"Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors"

https://clinicaltrials.gov/ct2/show/NCT01632696?term=peregrine+pharmaceuticals&rank=14

The high value of the "Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies" is the ability to diagnose this ovarian tumor type at an earlier stage than has been previously possible. It should be a real lifesaver for many women in the future of ovarian oncology.

IMO

sunstar